UNSPSC 51422364: Prednisolone sodium phosphate

This classification denotes a therapeutic glucocorticoid with the molecular formula C21H27O8P.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IV021NXA9J, chemically known as 3,20-dioxo-11beta,17alpha,21-trihydroxy-1,4-pregnadiene but more generally known as prednisolone sodium phosphate, which bears US NIH Compound Identifier 5755. European Medicines Agency schedules Prednisolone sodium phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04018MIG.

UNSPSC 51422364 Prednisolone sodium phosphate is a Commodity code, but the recent state and local opportunities tagged under it do not reflect pharmaceutical ingredient procurement. Instead, the posted solicitations are for finished naloxone products and direct-to-manufacturer prescription program management — neither of which aligns with the code's nominal scope of a corticosteroid pharmaceutical ingredient. Seminole County, Florida released an IFB in June 2026 for naloxone and drug deactivation systems (1,900 units and 800 units annually, respectively), with quarterly deliveries to a community health building and a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted an RFI in April 2026 seeking vendor capabilities for a direct-to-manufacturer prescription program that would establish relationships between the state's pharmacy benefit program and pharmaceutical manufacturers outside traditional PBM and GPO channels. Neither opportunity involves prednisolone sodium phosphate as a commodity line item or ingredient procurement.

The code shows minimal relevant recent activity under its nominal definition. The issuing bodies — a county health department and a state health and human services agency — are consistent with public-sector healthcare procurement patterns, and activity is geographically dispersed across Florida and Texas. However, because the posted opportunities do not reflect actual procurement of the pharmaceutical ingredient named in the code, this UNSPSC classification appears misaligned with the opportunities' scope. Firms evaluating whether to pursue activity under this code should verify the specific product line items and ingredient specifications in any future RFP or IFB release before committing resources, as the current opportunity set does not indicate demand for prednisolone sodium phosphate as a standalone commodity.